HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

IRRITABLE BOWEL SYNDROME: SOME ASPECTS OF PATHOGENESIS AND COMBINATION THERAPY

Download full text PDF
Issue: 
10
Year: 
2016

Professor A. Sarsenbaeva, MD; A. Smolyagina, K. Ufimtsev, Candidate of Medical Sciences; E. Ivanova South Ural State Medical University, Chelyabinsk

The authors have studied the expression of alleles and genotypes of key cytokines in the pathogenesis of irritable bowel syndrome (IBS) and evaluated the efficiency of treatment in patients with IBS during standard and combination therapy using Zakofalk.

Keywords: 
irritable bowel syndrome
cytokines
combination treatment
Zakofalk



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Drossman D., Corrazziari E., Delvaux M. et al. Rome III: The Functional Gastrointestinal Disorders. 3rd ed. / McLean, VA: Degnon Associates, 2006; 374–81.
  2. Hungin A., Whorwell P., Tack J. et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects // Aliment Pharmacol. Ther. – 2003; 17: 643–50.
  3. Quigley E., Bytzer P., Jones R. et al. Irritable bowel syndrome: the bur–den and unmet needs in Europe // Dig. Liver Dis. – 2006; 38: 717–23.
  4. Sperber A., Shvartzman P., Friger M. et al. A comparative reappraisal of the Rome II and Rome III diagnostic criteria: are we getting closer to the 'true' prevalence of irritable bowel syndrome? // Eur. J. Gastroenterol. Hepatol. – 2007; 19: 441–7.
  5. Sperber A., Shvartzman P., Friger M. et al. Unexpectedly low prevalence 5. rates of IBS among adult Israeli Jews // Neurogastroenterol. Motil. – 2005; 17: 207–11.
  6. Fox M., Yang J., Zhu Y. et al. Mechanism of lactose intolerance in irritable bowel syndrome: role of anxiety, mucosal immunity and visceral hypersensitivity. 21.UEGW. Abstracts // UEGJournal. – 2013; 1 (Suppl. 1): 110.
  7. Brandt L., Chey W., Foxx-Orenstein A. et al. An evidence-based systematic review on the management of irritable bowel syndrome // Am. J. Gastroenterol. – 2009; 104 (Suppl. 1): 8–34.
  8. Madisch A., Miehlke S., Bethke B. et al. Is there any association of microscopic . colitis and irritable bowel syndrome // Gut. – 2004; 51 (Suppl. 6): 134.
  9. Bennet E., Kellow E. Relations between chronic stress and bowel symptoms. Irritable bowel syndrome. Diagnosis and treatment. Ed. Camilleri M., Spiller M.C. / London: W.B. Saunders, 2002; p. 27–36.
  10. Lin H. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome // JAMA. – 2004; 292: 852–8.
  11. Pimentel M., Chow E., Lin H. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome // Am. J. Gastroenterol. – 2000; 95: 3503–6.
  12. Lupascu A., Gabrielli M., Lauritano E. et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome // Aliment. Pharmacol. Ther. – 2005; 22: 1157–60.
  13. Nucera G., Gabrielli M., Lupascu A. et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth // Aliment. Pharmacol. Ther. – 2005; 21: 1391–5.
  14. Pimentel M., Chow E., Lin H. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome // Am. J. Gastroenterol. – 2003; 98: 412–9.
  15. Pimentel M., Chow E., Lin H. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome // Am. J. Gastroenterol. – 2000; 95: 3503–6.
  16. Ringel Y., Williams R., Kalilani L. et al. Prevalence, characteristics, and 16. impact of bloating symptoms in patients with irritable bowel syndrome // Clin. Gastroenterol. Hepatol. – 2009; 7: 68–72.
  17. Delgado-Aros S., Camilleri M. Visceral hypersensitivity 2 // J. Clin. Gastroenterol. – 2005; 39: 194–20.
  18. Longstreth G., Thompson W., Chey W. et al. Functionalboweldisorders // Gastroenterology. – 2006; 130: 1480–91.
  19. Ortiz-Lucas M. Irritable bowel syndrome immune hypothesis. Part two: the role of cytokines / M. Ortiz-Lucas, P. Saz-Peiro, J. Sebastian-Domingo // Rev. Esp. Enferm. Dig. – 2010; 102: 711–7.
  20. Ivashkin V.T., Poluektova E.A. Effektivnost' lechenija patsientov s funktsional'nymi rasstrojstvami v Rossii. Rezul'taty nabljudatel'nogo issledovanija s uchastiem 500 bol'nyh, stradajuschih sindromom razdrazhen-nogo kishechnika (SRK) i SRK v sochetanii s funktsional'noj dispepsiej (FD). 93-ja Mezhdunarodnaja vesennjaja sessija Natsional'noj shkoly gastroenterolo-gii, gepatologii RGA, M., 2016.
  21. Nemtsov V.I. Sindrom razdrazhennoj kishki (SRK): novye predstavle nija ob etiopatogeneze i lechenii // Lechaschij vrach. – 2015; 6: 60. Klinicheskie rekomendatsii po vedeniju bol'nyh s sindromom raz drazhennogo kishechnika. Rekomendatsii Rossijskoj gastroenterologicheskoj assotsiatsii // RZhGGK. – 2014; 2.
  22. Stashkevich D.S., Ivanova E.L., Burmistrova A.L. Vklad polimorfizma 23. genov tsitokinov IL-1RA, IL-1B, TNFα, IL-10 v variabel'nost' techenija sindro-ma razdrazhennogo kishechnika // Vestnik ChelGU. Biologija. – 2013; 7 (298): 18–20.
  23. Ardatskaja M.D., Topchij T.B., Loschinina Ju.N. i dr. Klinicheskaja 24. effektivnost' masljanoj kisloty i inulina v kupirovanii bolevogo sin-droma u patsientov s sindromom razdrazhennoj kishki // Lechaschij vrach. – 2015; 12: 79.